The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 08, 2025

Filed:

May. 10, 2022
Applicants:

National University of Singapore, Singapore, SG;

Nkarta, Inc., South San Francisco, CA (US);

Inventors:

Jun Hao Leong, Singapore, SG;

Noriko Shimasaki, Singapore, SG;

See Voon Seow, Singapore, SG;

Dario Campana, Singapore, SG;

James Barnaby Trager, Albany, CA (US);

Alexandra Leida Liana Lazetic, San Jose, CA (US);

Chao Guo, San Francisco, CA (US);

Luxuan Guo Buren, San Francisco, CA (US);

Shyam Sashikant Masrani, London, GB;

Assignees:

National University of Singapore, Singapore, SG;

Nkarta, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7056 (2013.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C12N 15/625 (2013.01); C07K 14/70578 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.


Find Patent Forward Citations

Loading…